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1 |  INTRODUCTION
Steroid‐responsive encephalopathy associated with autoim-
mune thyroiditis (SREAT), also known as Hashimoto's en-
cephalopathy (HE), is a rare but probably underdiagnosed 
disease.1-4 The estimated prevalence is 2.1 per 100.000.4 HE 
can present with various symptoms, usually with acute or 
subacute onset. Confusion, memory impairment, speech dis-
order, gait disturbance, myoclonus, hallucinations, paranoia, 
depression, seizures, and coma are examples of symptoms 
described in the literature.1-10
The disease is associated with elevated levels of anti‐thy-
roid peroxidase (TPO) and/or anti‐thyroglobulin (TG).1-3,9 
The thyroid‐stimulating hormone (TSH) level is often 
normal. Elevated protein levels are typically seen in the 
cerebrospinal fluid; pleocytosis may also be present. EEG 
findings are often abnormal but nonspecific with general-
ized slowing. MRI findings can be normal or show nonspe-
cific features.1,2
High doses of steroids are used as first‐line treatment.1 
Full or partial clinical remission is common, but some pa-
tients may experience one or several relapses and therefore 
require repeated treatments.1,2
2 |  CASE REPORT
A 66‐year‐old man, without any prior history of neurologi-
cal diseases, was referred to the regional memory clinic in 
March 2014 due to subacute symptoms developing over a 
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Abstract
Hashimoto's encephalopathy is a rare disease with nonspecific symptoms, associated 
with elevated levels of anti‐TPO and/or anti‐TG. It can be potentially fatal. However, 
it is responsive to steroid and treated in due time, it can be fully reversible.
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few weeks followed by 6‐9  months of progressive symp-
toms. The patient had problems with performing daily prac-
tical tasks. He described memory impairment, progressive 
problems with his speech, dizziness, fluctuating awareness, 
balance problems, apraxia, twitching of the upper and lower 
extremities, mood changes, and hallucinations. The objective 
neurological examination showed discreet aphasia and dys-
arthria, discreet bilateral resting tremor, truncal instability, 
T A B L E  1  Selected neuropsychological test data before and after treatment with steroids
  June 2014 November 2014
Test Score Percentiles/scale score Score Percentiles/scale score
Continuous subtraction 
(100‐7)
0/0 (135 sec, 6 errors)   10/10 (40 sec, 0 errors)  
Trail making B Gives up after 3 min   173 sec, 1 error >10 pctl
Stroop Dots: 50 sec, 0 errors
Color words: 172 sec, 17 
errors
  Dots: 40 sec, 0 errors
Color words: 79 sec, 1 error
 
ADAS‐COG Mean error score 5, recalls 
6/10
  Mean error score 2, recalls 
9/10
 
Fluency
animals 14 8 pctl 24 66 pctl
s‐words 10 28 pctl 15 64 pctl
Matrix Reasoning 
(WAIS‐IV)
5/26 Scale score 3 10/26 Scale score 7
Design fluency Gives up   20 27 pctl
Picture Arrangement 
(WAIS‐III)
1/22 Scale score 2 7/22 Scale score 7
F I G U R E  1  18F‐FDG‐PET before and after treatment with steroids (ca. 6 months between the two scans)
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myoclonus and severe bilateral apraxia, and dysdiadochoki-
nesia. The finger‐nose‐finger test showed accentuated bilat-
eral tremor. The Mini‐Mental State Examination Score was 
25/30 points (normally >26). The neuropsychological exami-
nation described a cognitive profile with a dysexecutive/sub-
cortical picture. The patient fulfilled the formal criteria for 
dementia (see Table 1).
Cerebral CT had previously excluded subdural hematoma 
and supplemental MRI showed normal findings. Chest X‐
Ray and full‐body‐PET showed no signs of extra‐cerebral 
malignancy. Also, test results for paraneoplastic antibodies 
in blood were normal. There were negative biomarkers for 
Alzheimer's dementia (Aß42, F‐tau; P‐tau) in the cerebrospi-
nal fluid, but elevated levels of both protein and leukocytes. 
The patient was tested negative for Lyme disease. Brain‐
FDG‐PET findings showed decreased global cortical glucose 
metabolism (see Figure 1), interpreted as not indicative of a 
neurodegenerative etiology, but rather suggestive of a meta-
bolic or toxic effect on cerebral metabolism.
Supplemental blood tests were ordered, including thy-
roid antibodies. The anti‐TG level in serum was 879 (normal 
range <115). Other blood tests were normal, including anti‐
TPO, TSH, ferroxidase, and copper. As HE was suspected, 
treatment with oral prednisolone was initiated.
The patient showed clinical improvement after just a few 
days of treatment, with approximate subjective remission 
after 2 weeks. A significant improvement of the cerebral glu-
cose metabolism was seen on the brain‐FDG‐PET performed 
2 months after the treatment (see Figure 1). A neuropsycho-
logical re‐examination showed remarkable improvement 
compared with previous examinations (see Table 1.). After 
the end of treatment, the patient experienced four relapses 
in total, in the period up to January 2016. Each time, he was 
treated with oral prednisolone with positive clinical response 
as a result. He received the last treatment in February 2016, 
and at the follow‐up afterward, there were no signs of further 
relapses. The relumbar puncture, performed due to the last 
relapse in 2016, showed that there were still elevated levels 
of protein and leukocytes in the cerebrospinal fluid prior to 
re‐institution of steroid treatment. Thyroid antibodies and 
tests for other types of autoimmune encephalitis were nega-
tive. The MRI was still normal. Screening blood tests for con-
nective tissue disorders were also normal. In August 2017, 
the patient had not shown symptoms for over a year and was 
therefore declared cured.
3 |  DISCUSSION
Hashimoto's encephalopathy is a rare disease, but probably 
also underdiagnosed.1-3,6 The exact relationship between 
the anti‐thyroid antibodies and the encephalopathy is still 
unknown.1,9,10 To our knowledge, there are no previous 
publications presenting follow‐up data from both FDG‐PET 
and neuropsychological examination, respectively, before 
and after treatment.
There is no diagnostic test available for HE, and the differ-
ential diagnosis is broad. Therefore, other possible etiologies 
must be excluded before making the diagnosis.3,7 Etiologies 
that should be considered prior to making the diagnosis of 
HE, include CNS infection, inflammatory conditions such as 
systemic lupus, and neurodegenerative diseases such as CJD, 
paraneoplastic limbic encephalitis, and vascular causes.7,10 
The patient in our case was screened negative for vascular, 
paraneoplastic and infectious causes, connective tissue disor-
ders, and other autoimmune causes. Alzheimer's disease was 
also ruled out.
If a patient presents with rapidly progressive dementia or 
subacute encephalopathy with unspecific symptoms and nor-
mal test results, without other obvious etiologies, HE should 
be considered, also with normal levels of TSH 1-3,10 and no 
pre‐existing thyroid disorder.1 In this case report, the anti-
body reaction may be regarded as the triggering factor, and 
the elevated levels of protein and the pleocytosis in the cere-
brospinal fluid were due to an ongoing inflammatory process 
in the central nervous system, despite negative antibodies at 
relapse. There are several cases described in the literature 
where only one of the antibodies has been elevated,1,8 and 
there has not been proven a correlation between the antibody 
level and the severity of clinical symptoms.2,9 The patient was 
treated many times due to relapses, but experienced full neu-
rological remission, without any further relapses, after the last 
treatment. A fast initiation of treatment is crucial, to avoid ir-
reversible, potentially fatal complications.6 Knowledge of the 
disease is important, despite its rarity, because it can be fully 
reversible if treated in due time.3,8,9
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